Back to Journals » OncoTargets and Therapy » Volume 9

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors

Authors Kotteas E, Syrigos K, Saif MW

Received 7 September 2015

Accepted for publication 21 December 2015

Published 9 February 2016 Volume 2016:9 Pages 699—704

DOI https://doi.org/10.2147/OTT.S72155

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 3

Editor who approved publication: Professor Daniele Santini


Elias A Kotteas,1 Konstantinos N Syrigos,1,2 Muhammad Wasif Saif3

1Oncology Unit, Sotiria General Hospital, University of Athens, Athens, Greece; 2Thoracic Oncology Program, Yale School of Medicine, New Haven, CT, USA; 3Section of GI and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, USA

Abstract: Neuroendocrine tumors are a rare and heterogeneous group of tumors with a variety of primary origins and variable aggressiveness. Platinum-based chemotherapy has been the cornerstone of treatment for the poorly differentiated tumors. However, well-differentiated neuroendocrine tumors are quite chemoresistant and therapy options are limited. Octreotide analogs and tyrosine kinase inhibitors are widely acceptable treatments due to substantial efficacy and tolerable toxicity. On the contrary, monotherapy or combinations of the only approved cytotoxic agent streptozocin with other drugs have been almost abandoned because of excessive toxic events. In recent years, the combination of capecitabine and temozolomide has emerged as the most promising and efficacious treatment. The oral route of administration and the substantial improvement in the outcomes with manageable toxicity are the major advantages. We reviewed the current literature and presented the profile of the capecitabine/temozolomide combination in the management of well-differentiated neuroendocrine tumors.

Keywords:
capecitabine, neuroendocrine tumors, octreotide analogs, streptozocin, temozolomide, toxicity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]